UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

______________

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): ~~October~~November 2017, 2015

SKYSTAR BIO-PHARMACEUTICAL COMPANY

(Exact Name of Registrant as Specified in Its Charter)

Nevada

(State or Other Jurisdiction of Incorporation)

001-34394		33-0901534
(Commission File Number)		(IRS Employer Identification No.)

4/F Building B Chuangye Square, No. 48 Keji Road, Gaoxin District, Xi’an Shaanxi Province, P.R. China		n/a
(Address of Principal Executive Offices)		(Zip Code)

(8629) 8819-3188

(Registrant’s Telephone Number, Including Area Code)

n/a

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 3.01

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

On ~~October~~November 2017, 2015, Skystar Bio-Pharmaceutical Company (the “Company”) received a notification from ~~the~~The Nasdaq Stock Market (“Nasdaq”) informing the Company that ~~is was subject to delisting~~ because it ~~failed~~had tonot ~~comply~~filed ~~with~~its ~~Nasdaq’s~~Quarterly ~~filing~~Report ~~requirements~~on ~~set forth in Listing Rule 5250(c)(1) because it failed to file its~~ Form 10-KQ for the ~~fiscal~~quarter ~~year~~ ended ~~December~~September 3130, ~~2014, and Forms~~2015(the ~~10-Q~~“Quarterly ~~for~~Report”), the ~~periods~~Company ~~ended~~was ~~March~~not ~~31,~~in ~~and~~compliance ~~June~~with ~~30,~~Nasdaq ~~2015~~Listing Rule 5250(c)(1).

~~Nasdaq~~The ~~also notified the~~ Company ~~of two additional, and separate, bases for delisting under Listing Rule 5250(b)(1) (failure to disclose material non-public~~previously ~~information)~~disclosed ~~and~~a ~~Listing~~notification ~~Rule~~from ~~5101 (public interest concerns). The information to which~~ Nasdaq ~~referred was~~informing the ~~conduct by the~~ Company’s ~~audit~~that ~~committee~~is ofwas ansubject ~~internal~~to ~~investigation~~delisting ~~into~~because ~~certain~~it ~~allegations,~~failed ~~raised~~to bycomply ~~the~~with ~~Company~~Nasdaq’s ~~auditors,~~filing ~~that~~requirements ~~the~~set ~~auditors~~forth ~~had~~in ~~been~~Listing ~~presented~~Rule by5250(c)(1) ~~Company~~because ~~personnel~~it ~~with~~failed ~~false bank documents relating~~ to ~~one~~file ~~bank~~its ~~account.~~Form ~~The public~~10-K ~~interest~~for ~~concerns arise from~~ the ~~audit~~fiscal ~~committee’s~~year ~~determination~~ended ~~that~~December 31, a2014, ~~low~~and ~~level~~Forms ~~employee~~10-Q ~~had~~for ~~falsified~~the ~~bank~~periods ~~documents relating~~ended toMarch ~~one~~31, ~~bank~~and ~~account~~June 30, ~~which~~2015. ~~were~~The ~~then~~failure ~~provided~~ to file the ~~auditors~~Quarterly byReport ~~other~~constitutes an ~~Company~~additional ~~personnel~~basis ~~who~~for ~~were unaware of the falsehood~~delisting. The ~~employee~~Company ~~who~~also ~~falsified~~previously ~~the~~disclosed ~~document~~that isNasdaq nohad ~~longer~~notified ~~with~~ the Company. ~~After~~of ~~the~~two ~~audit committee concluded its investigation~~additional, ~~the~~ ~~Company’s~~and ~~external~~separate, ~~auditors~~bases ~~have~~for ~~resumed~~delisting ~~their~~under ~~audit~~Listing ofRule ~~the~~5250(b)(1) ~~Company’s~~(failure ~~financial~~to ~~statements~~disclose ~~for~~material ~~the~~non-public ~~year~~information) ~~ended~~and ~~December~~Listing ~~31,~~Rule ~~2014.~~5101 (public interest concerns).

The Company ~~intends~~has a hearing toscheduled ~~request~~for aDecember ~~review~~3, of2015 for the ~~delisting~~hearing ~~determination~~panel byto ~~Nasdaq’s~~review ~~Listing~~the ~~Qualifications~~delisting ~~Panel~~determination.

Item 8.01

Other Events

On ~~October~~November 2319, 2015, the Company issued a press release relating to the foregoing event, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01

Financial Statements and Exhibits.

(d)

Exhibits.

99.1 Press release dated ~~October~~November 2319, 2015.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: ~~October~~November 2320, 2015

SKYSTAR BIO-PHARMACEUTICAL COMPANY By: /s/ Bing Mei Name: Bing Mei Title: ~~Bing~~Chief ~~MeiChief~~ Financial Officer

Filing Compare · SKYSTAR BIO-PHARMACEUTICAL CO